Endeavour Silver (EXK) Sets New Record for Mine Production in Q4, 2009

VANCOUVER, BRITISH COLUMBIA–(Marketwire – 01/13/10) – Endeavour Silver Corp. (TSX:EDR – News)(TSX:EDR.WT – News)(AMEX:EXK – News)(DBFrankfurt: EJD) announces that the Company set a new record for silver production in Q4, 2009, up 12% quarter-on-quarter to 779,345 oz silver. Gold production also jumped to a new quarterly high, up 90% to 4,591 oz gold in Q4, 2009.

Endeavour delivered its fifth consecutive year of silver production growth in 2009, up 11% year-on-year to 2.6 million oz silver. In addition, gold production rose even more sharply, up 66% to 13,298 oz gold in 2009 compared to 2008. Using the current silver:gold ratio of 62:1 (base metals not included as equivalents), Endeavour produced 3.4 million oz silver equivalents in 2009, up 21% compared to 2008.

These new Company highs for silver and gold production can largely be attributed to the successful expansion programs at the Company’s two operating silver mines in Mexico, the Guanacevi Mine in Durango State and the Guanajuato Mine in Guanajuato State. Substantial organic growth potential remains to be realized at the two mines in order to reach their +4 million oz per year capacity.

Endeavour also enjoyed its best-ever unaudited quarterly and annual financial results in 2009 since the commencement of mining operations in 2004. Although the annual audited financial statements will not be ready until late March, based on production and sales results to December 31, 2009, management provides the following estimates of financial results for fiscal 2009: sales revenues will exceed US$50 million, costs of sales are expected to be less than US$31 million, Q4 cash costs should come in below the US$5.20 per oz recorded in Q3 and average around US$6 per oz silver for 2009.

To view a video with Chairman and CEO Bradford Cooke’s commentary on the 2009 production data, click here: http://www.edrsilver.com/i/media/2010-01-13_NRV.html

Bradford Cooke, Chairman and CEO, commented, “We are happy to announce that Endeavour delivered its fifth consecutive year of production growth in 2009. We also succeeded in driving our cash costs of silver production down to almost half of where they were 18 months ago. Our mine operations teams are to be congratulated for doing a great job in 2009, notwithstanding the difficult start to the year thanks to the global financial crisis and various operating issues that resulted in several days of lost production.”

“Management is of the belief that the silver price will continue to appreciate in 2010 so we plan to continue accelerating our exploration drilling, mine development and plant refurbishment programs this year in order to ensure continued aggressive production growth. We expect to achieve our 6th consecutive year of organic production growth this year as well as growth through acquisitions in 2010.”

Endeavour plans to release an overview of its 2009 exploration activities including new drilling results within the next two weeks; a more detailed review of its 2009 mining operations and 2010 production forecast in February; the annual update of NI 43-101 reserves and resources by early March; and the 2009 audited financial results and outlook will be released in late March, 2010.

Endeavour Silver Corp. is a small-cap silver mining company focused on the growth of its silver production, reserves and resources in Mexico. Since start-up in 2004, Endeavour has posted five consecutive years of growing silver production and resources. The organic expansion programs now underway at Endeavour’s two operating silver mines in Mexico combined with its strategic acquisition program should help propel Endeavour to become the next premier mid-tier primary silver producer.

ENDEAVOUR SILVER CORP.

Bradford Cooke, Chairman and CEO

CAUTIONARY DISCLAIMER – FORWARD LOOKING STATEMENTS

This news release contains “forward-looking statements” within the meaning of the United States private securities litigation reform act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking statements and information herein include, but are not limited to, statements regarding Endeavour’s anticipated performance in 2010, including silver and gold production, timing and expenditures to develop new silver mines and mineralized zones, silver and gold grades and recoveries, cash costs per ounce, capital expenditures and sustaining capital and the use of proceeds from the Company’s recent financing. The Company does not intend to, and does not assume any obligation to update such forward-looking statements or information, other than as required by applicable law.

Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Endeavour and its operations to be materially different from those expressed or implied by such statements. Such factors include, among others: fluctuations in the prices of silver and gold, fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and U.S. dollar); changes in national and local governments, legislation, taxation, controls, regulations and political or economic developments in Canada and Mexico; operating or technical difficulties in mineral exploration, development and mining activities; risks and hazards of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected geological conditions, pressures, cave-ins and flooding); inadequate insurance, or inability to obtain insurance; availability of and costs associated with mining inputs and labour; the speculative nature of mineral exploration and development, diminishing quantities or grades of mineral reserves as properties are mined; the ability to successfully integrate acquisitions; risks in obtaining necessary licenses and permits, and challenges to the company’s title to properties; as well as those factors described in the section “risk factors” contained in the Company’s most recent form 40F/Annual Information Form filed with the S.E.C. and Canadian securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or information, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements or information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information.

The TSX Exchange has neither approved nor disapproved the contents of this news release.

Simulations Plus (SLP) Reports First Quarter FY2010 Financial Results

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ:SLP – News), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2010 ended November 30, 2009 (1QFY10).

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “I’m pleased to report that our consolidated net sales increased 14.2% to $2,437,000 in 1QFY10 from $2,133,000 in the first fiscal quarter of fiscal 2009 (1QFY09). Sales for our pharmaceutical software and services business increased 21.3%, or $305,000, for 1QFY10 over 1QFY09. Revenues from our Words+ subsidiary were essentially flat, with a 0.1% decrease over 1QFY09.”

Ms. Beran continued: “For 1QFY10, consolidated gross profit increased 16.2% to $1,830,000 from $1,574,000 in 1QFY09. R&D expense decreased 2.9% to $261,000 in 1QFY10 from $269,000 in 1QFY09 due to more staff hours being spent on consulting studies in 1QFY10. Total R&D expenditures, which include capitalized software development costs, decreased by 1.9% to $462,000 from $471,000. Consolidated SG&A increased $100,000, or 11.1% to $1,004,000 in 1QFY10, compared to $904,000 in 1QFY09. As a percentage of sales, SG&A decreased to 41.2% in 1QFY10 from 42.4% in 1QFY09. Expanded travel and trade show expenses accounted for a significant portion of the increase as we have increased our marketing and sales efforts substantially over last year. For 1QFY10, net income before taxes increased 46.0%, or $208,000, to $661,000 compared with $453,000 in 1QFY09. Our provision for income taxes increased by 63.7%, or $90,000, to $231,000 (estimated tax rate of 35.0%) for 1QFY10 from $141,000 (tax rate of 31.2%) in 1QFY09. Using our best estimates for the remainder of the year, we anticipate a tax rate for the year to be in the range of 33-37%; however, this will depend on the tax credits we obtain from Non-qualified Incentive Stock Option events and the amount of R&D tax credits generated during the current fiscal year.

“Consolidated net earnings for 1QFY10 were $430,000, or $0.03 per fully diluted share, an increase of 38.0% from $312,000, or $0.02 per diluted share in 1QFY09. We attribute this to our increased revenues from pharmaceutical software licenses and consulting services, which offset the increase in our investment in marketing and sales. Our cash continues to grow, with cash at the end of 1QFY10 of $7,973,000, up 31.5% from $6,064,000 at the end of 1QFY09. Shareholders’ equity increased 4.8% from $10,315,004 on November 30, 2008, to $10,811,665 on November 30, 2009. Note that this was after we spent just over $1 million for share repurchases during the past year.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “These results represent a new record first quarter for both revenues and earnings. We believe much of the growth is the result of the aggressive marketing and sales program we began early in 2009, wherein we have attended approximately three times as many scientific meetings and trade shows compared to what we had typically done in previous years. The recognition we’ve received through scientific presentations by our industry and government customers at many of these scientific meetings has also undoubtedly contributed to our success. With the upcoming release of GastroPlus™ Version 7.0, which will add three very important new capabilities in drug-drug interaction, ocular drug delivery, and nasal/pulmonary drug delivery, and coming improvements in ADMET Predictor™, ClassPharmer™, and DDDPlus™, combined with the continued strong demand for our consulting services, we expect 2010 to continue to be a very good year.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. We have two other businesses that are based on our proprietary technologies: a wholly owned subsidiary, Words+, Inc., which provides assistive technologies to persons with disabilities as well as a personal productivity tool for the mass market called Abbreviate! ^™; and an educational software series for science students in middle and high schools known as FutureLab^™. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

Mindspeed (MSPD) Announces Preliminary Fiscal First Quarter 2010 Results

Jan. 13, 2010 (Business Wire) — Mindspeed Technologies, Inc. (NASDAQ:MSPD), a leading supplier of semiconductor solutions for network infrastructure applications, today announced preliminary results for its fiscal first quarter of 2010, which ended on January 1, 2010. The company now expects revenues in its fiscal first quarter of 2010 to be approximately $37.0 million. The company’s previous guidance for fiscal first quarter revenue was to be in the range of $36.1 million to $37.5 million.

In addition, the company now anticipates non-GAAP gross margin for its fiscal first quarter to be approximately 63.7 percent, exceeding previous guidance of 62.5 to 63.0 percent, and GAAP gross margin to be approximately 63.6 percent. The company also expects non-GAAP operating expenses to be approximately $21.3 million and GAAP operating expenses to be approximately $23.1 million, resulting in non-GAAP earnings per share of approximately $0.07 and GAAP loss per share of approximately $(0.01). The approximate non-GAAP earnings per share is the highest level of profitability the company has achieved as a public company, excluding the benefit from patent sales in previous periods.

“We are very pleased with the progress in our business model as evidenced by the strong operating performance, profitability and cash generation that we expect for the fiscal first quarter of 2010. Overall, we were also pleased with the market trends and the demand dynamics in the fiscal first quarter, which met or exceeded our expectations at the beginning of the quarter. Importantly, we are currently participating in multiple, exciting growth product cycles within our multiservice access (MSA) and high-performance analog (HPA) businesses and are continuing to see strengthening, broad-based, global demand from numerous tier one customers, particularly in China,” said Raouf Halim, chief executive officer of Mindspeed.

Mindspeed is scheduled to release its final earnings results for the fiscal first quarter of 2010 on January 25, 2010.

Fiscal First Quarter 2010 Conference Call

Mindspeed will conduct a conference call announcing its fiscal first quarter 2010 results on Monday, January 25, 2010, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. To listen to the conference call via telephone, call 800-593-9968 (domestic) or 210-795-2680 (international); password: Mindspeed. To listen via the Internet, please visit the Investors section of Mindspeed’s web site at www.mindspeed.com. Replay of the conference will be available via telephone one hour after it concludes for a period of 30 days by calling 888-568-0879 (domestic) or 203-369-3206 (international). Replay will also be available on Mindspeed’s web site at www.mindspeed.com during such 30 day period.

About Mindspeed Technologies®

Mindspeed Technologies, Inc. designs, develops and sells semiconductor solutions for communications applications in the wireline and wireless network infrastructure, which includes today’s separate but interrelated and converging enterprise, broadband access, metropolitan and wide area networks. Our products are classified into three focused product families: multiservice access, high-performance analog and wide area networking communications. Our products are sold to original equipment manufacturers (OEMs) for use in a variety of network infrastructure equipment, including voice and media gateways, high-speed routers, switches, access multiplexers, cross-connect systems, add-drop multiplexers, digital loop carrier equipment, IP private branch exchanges (PBXs), optical modules, broadcast video systems and wireless base station equipment.

Safe Harbor Statement

We are unable to provide a reconciliation of the preliminary non-GAAP measures to GAAP measures because we have not yet determined final numbers for items such as special charges, asset impairments, employee separation costs and stock-based compensation related expenses. For a discussion of our use of non-GAAP financial measures, please refer to our earnings release dated October 26, 2009 and our Current Report on Form 8-K furnished to the SEC on the same date. A complete reconciliation of non-GAAP measures to GAAP measures will be provided when we release final earnings results for the fiscal first quarter of 2010 on January 25, 2010.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include statements regarding the company’s expectations, goals or intentions, including, but not limited to, expected levels of revenue, gross margin and earnings and loss per share, which are preliminary and subject to change as we complete our review of the first quarter of fiscal 2010, the strength of our operating performance, growth product cycles, product demand, market trends and cash generation. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about the company and are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: cash requirements and terms and availability of financing; future operating losses; worldwide political and economic uncertainties, and specific conditions in the markets we address; fluctuations in the price of our common stock and our operating results; loss of or diminished demand from one or more key customers or distributors; our ability to attract and retain qualified personnel; constraints in the supply of wafers and other product components from our third-party manufacturers; pricing pressures and other competitive factors; successful development and introduction of new products; doing business internationally and our ability to successfully and cost effectively establish and manage operations in foreign jurisdictions; industry consolidation; order and shipment uncertainty; our ability to obtain design wins and develop revenues from them; lengthy sales cycles; the expense of and our ability to defend our intellectual property against infringement claims by others; product defects and bugs; business acquisitions and investments; and our ability to utilize our net operating loss carry-forwards and certain other tax attributes. Risks and uncertainties that could cause the company’s actual results to differ from those set forth in any forward-looking statement are discussed in more detail under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s Annual Report on Form 10-K for the year ended October 2, 2009, as well as similar disclosures in the company’s subsequent SEC filings. Forward-looking statements contained in this press release are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Amtech (ASYS) Announces $59 Million in Total Orders for the December Quarter

Jan. 13, 2010 (Business Wire) — Amtech Systems, Inc. (NASDAQ:ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and silicon wafers, today announced that orders booked for its fiscal 2010 first quarter ended December 31, 2009 totaled approximately $59 million. This total includes both solar and semiconductor orders including the large solar order from an existing customer announced on December 18, 2009. A significant portion of these orders are expected to ship within fiscal 2010.

J.S. Whang, President and Chief Executive Officer of Amtech, commented, “We are extremely pleased with the substantial increase in orders from our large and growing solar customer base and we remain confident in the long-term growth opportunities in the solar market for our products.”

About Amtech Systems, Inc.

Amtech Systems, Inc. manufactures capital equipment, including silicon wafer handling automation, thermal processing equipment and related consumables used in fabricating solar cells and semiconductor devices. Semiconductors, or semiconductor chips, are fabricated on silicon wafer substrates, sliced from ingots, and are part of the circuitry, or electronic components, of many products including solar cells, computers, telecommunications devices, automotive products, consumer goods, and industrial automation and control systems. The Company’s wafer handling, thermal processing and consumable products currently address the diffusion, oxidation, deposition, PECVD, and PSG removal steps used in the fabrication of solar cells, semiconductors, MEMS and the polishing of newly sliced silicon wafers.

Statements contained in this press release that are not historical facts may be forward looking statements within the meaning of the Private Litigation Reform Act. Such statements may use words such as “proposed,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “predict,” “project” and similar expressions as they relate to Amtech Systems, Inc. or our management. When we make forward-looking statements, we are basing them on our management’s beliefs and assumptions, using information currently available to us. Although we believe that the expectations reflected in the forward looking statements are reasonable, these forward-looking statements are subject to risks, uncertainties and assumptions including the risks discussed in our filings with the Securities and Exchange Commission. If one or more of these risks materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we projected. Any forward looking statements contained in this press release reflect our current views with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We have no intention, and disclaim any obligation, to update or revise any forward-looking statements, whether as a result of new information, future results or otherwise.

Johns Hopkins University Researchers Demonstrate miRview(TM) squamous Classifies Non-Small Cell Lung Cancer with Extremely High Degree of Accuracy

Jan. 13, 2010 (Business Wire) — Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the Department of Pathology at Johns Hopkins University School of Medicine were published online yesterday, January 12^th, and are set to be published in the January 15, 2010 issue of the American Association for Cancer Research’s journal Clinical Cancer Research. The study, ”Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach,” shows that Rosetta Genomics’ miRview™ squamous test accurately classified NSCLC samples both from resections, as well as from fine-needle aspirate (FNA) cell blocks. The abstract of the study may be viewed online at the Clinical Cancer Research’s website: http://clincancerres.aacrjournals.org/content/early/2010/01/10/1078-0432.CCR-09-2638.abstract

miRview™ squamous (offered in the U.S. by Prometheus Laboratories under the brand name ProOnc™ squamous), is a microRNA-based molecular assay that classifies NSCLC into squamous or non-squamous carcinomas using the expression level of a single microRNA biomarker.

In the study, 102 resected NSCLC samples were classified at JHU using “gold standard” methods (H&E staining) and additionally a panel of immunohistochemical stains, and later classified in a blinded fashion using the miRview™ squamous test at Rosetta Genomics Laboratories. The samples were classified as either squamous or non-squamous cell carcinoma. Results showed 100% concordance between the diagnoses established by methods exceeding the “gold standard” methods and miRview™ squamous for the resected NSCLC samples.

Corresponding preoperative biopsies/aspirates that had been originally diagnosed as poorly differentiated NSCLC were available for 21 cases. As a second phase of this study, these preoperative samples were analyzed by miRview™ squamous, and compared with the classification obtained following the patient’s surgery. miRview™ squamous correctly classified 20 of the 21 (95%) preoperative biopsy specimens.

Lung cancer is the leading cause of cancer mortality in the U.S., killing more than 160,000 Americans every year. In over 60,000 of these patients with NSCLC, identification of the squamous sub-type has significant clinical implications. Squamous lung cancer carries increased risk of severe or fatal bleeding for certain targeted biological therapies, including bevacizumab (Avastin™) and other drugs under development.¹ Other approved therapies, such as pemetrexed (Alimta™) are indicated for non-squamous NSCLC only.²

“There is a large and growing body of literature that demonstrates the limitations of ‘gold standard’ histopathology methods, as well as with immunohistochemical staining methods for classifying NSCLC,” said Tina Edmonston, M.D., Director of Rosetta Genomics’ CLIA-certified laboratory. “Studies show that when given the same sample, pathologists will disagree on the diagnoses in approximately 30% of the cases. With the recent emergence of targeted lung cancer therapies, such as Avastin™ and Alimta™, we need the most accurate classification possible for NSCLC. In addition, as other targeted drugs enter the clinical arena, accurate classification will become increasingly important to better assess differential side effects and efficacy profiles. We believe there is a definite need for objective, standardized, and reproducible molecular diagnostic assays that can reliably classify NSCLC.”

“This is an exciting study for us, as it validates miRview™ squamous’ sensitivity, specificity, reproducibility and overall reliability in helping physicians accurately make this critical lung cancer classification,” said Ken Berlin, President and CEO of Rosetta Genomics. “The outstanding performance of our miRview™ squamous test underscores our ability to harness the power of microRNAs through our proprietary technology platforms. We are using this ability to further unleash the promise of microRNA and to advance our pipeline of products and the standard of medical care.”

About microRNAs

MicroRNAs (miRNAs) are recently discovered, small RNAs that act as master regulators of protein synthesis, and have been shown to be highly effective biomarkers. MicroRNAs’ unique advantage as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block. It has been suggested that their small size (19-21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly in samples preserved by this method. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced. To learn more about microRNAs, please visit www.rosettagenomics.com.

About miRview™ Products

miRview™ are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview™ mets accurately identifies the primary tumor site in metastatic cancer and Cancer of Unknown Primary. miRview™ squamous accurately identifies the squamous subtype of NSCLC, which carries an increased risk of severe of fatal internal bleeding and poor response to treatment for certain therapies. miRview™ meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview™ tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, over 100,000 patients a year may benefit from the miRview™ mets test, 60,000 from miRview™ squamous, and 60,000 from miRview™ meso, with similar numbers of patients outside the U.S. The company’s tests are now being offered through distributors around the globe. For more information, please visit www.mirviewdx.com.

About Rosetta Genomics

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of the Wall Street Journal’s Technology Innovation Awards in the medical/biotech category. To learn more, please visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the potential applications of the miRview squamous test, the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta’s approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosetta’s ability to obtain, maintain and protect its intellectual property; Rosetta’s ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta’s need and ability to obtain additional funding to support its business activities; Rosetta’s dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta’s ability to successfully develop its products and services; Rosetta’s ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta’s technology; competition from others using technology similar to Rosetta’s and others developing products for similar uses; Rosetta’s dependence on collaborators; and Rosetta’s short operating history; as well as those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

NIVS (NIV) Introduces New 3G Surveillance Camera

HUIZHOU, China /PRNewswire-Asia/ — NIVS IntelliMedia Technology Group, Inc., (“NIVS” or the “Company”) (NYSE Amex: NIV), a consumer electronics company that designs, manufactures and sells intelligent audio and visual products, today announced that the Company has introduced to the marketplace a new 3G surveillance camera as a replacement to a previous model and expects that the product will be available for sale by mid-February.

The application for the new 3G surveillance camera includes security in a commercial or industrial environment or in a home setting for baby or child monitoring, as an example. The camera can be accessed via a mobile phone in addition to computer access. It is expected that the new camera will be marketed through China Unicom’s distribution network as well as the NIVS sales channels.

Mr. Tianfu Li, Chairman and CEO of NIVS, commented, “We are pleased to offer an improved version of our previous surveillance product and will continue working to upgrade our other electronics products offerings so as to remain at the forefront of innovation and the latest technologies.”

About NIVS IntelliMedia Technology Group, Inc.

NIVS IntelliMedia Technology Group is an integrated consumer electronics company that designs, manufactures, markets and sells intelligent audio and video products in China, Greater Asia, Europe, and North America. The NIVS brand has received “Most Popular Brand” distinction in China’s acoustic industry for three consecutive years, among numerous other awards. NIVS has developed leading Chinese speech interactive technology, which forms a foundation for the Company’s intelligent audio and visual systems, including digital audio, telecommunication, LCD televisions, digital video broadcasting (“DVB”) set-top boxes, peripherals and more.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward looking terminology such as “believes,” “expects” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including, but not limited to the Company’s ability to develop and market new products; the Company’s ability to continue to borrow and raise additional capital to fund its operations; the Company’s ability to accurately forecast amounts of supplies needed to meet customer demand; exposure to market risk through sales in international markets; the market acceptance of the Company’s products; exposure to product liability and defect claims; fluctuations in the availability of raw materials and components needed for the Company’s products; protection of the Company’s intellectual property rights; and changes in the laws of the PRC that affect the Company’s operations. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the discussed above and in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume an obligation to update these forward-looking statements.

Luna Innovations (LUNA) Emerges from Chapter 11 Reorganization

Jan. 12, 2010 (Business Wire) — Luna Innovations Incorporated (NASDAQ: LUNA), a company focusing on sensing, instrumentation and nanotechnology, announced today that it has emerged from Chapter 11 reorganization, less than six months after filing.

The Honorable William F. Stone, Jr. of the U.S. Bankruptcy Court for the Western District of Virginia, Roanoke Division, confirmed the company’s Joint Plan of Reorganization on Jan. 12, 2010. Luna’s reorganization plan provides that Luna’s creditors will receive a 100 percent recovery on their valid claims and that Luna’s current shareholders will retain their shares.

Luna voluntarily filed for reorganization under Chapter 11 of the U.S. Bankruptcy Code on July 17, 2009, in response to a potential negative outcome in its litigation with Hansen Medical, Inc. The two companies reached a settlement in December 2009, resolving the outstanding litigation between them. The settlement resulted in a development and supply agreement between Luna and Hansen, and a license of Luna’s fiber optic shape sensing technology to Hansen in the fields of medical robotics and certain medical non-robotics.

“Thank you to our customers, shareholders, partners and vendors for standing by us during this trying time,” stated Kent Murphy, Chief Executive Officer. “A special thanks goes to our employees for continuing to stay focused and providing our customers with excellent service and products during this difficult time. From the outset, our intent during this restructuring has been to continue to serve our customers, keep the pace of our key development initiatives, maintain employment at our four facilities in Virginia, settle with Hansen, provide our creditors with a full recovery on their valid claims, and allow current shareholders to retain their shares. Today, we can say we succeeded in those goals and did so in a relatively short time frame. Emerging from Chapter 11 will allow Luna to move forward on developing technologies that will provide tremendous value for our partners and customers. In addition, we appreciate Intuitive Surgical for its support and agreement, which was required to reach settlement, and Hansen for working hard to reach agreeable terms.”

More information about Luna’s Chapter 11 reorganization and subsequent emergence can be found on its Reorganization News Web page at http://www.lunainnovations.com/news/reorganization.htm.

About Luna Innovations:

Luna Innovations Incorporated (http://www.lunainnovations.com) is focused on sensing and instrumentation, and pharmaceutical nanomedicines. Luna develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. The company’s products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.

Forward-Looking Statements:

This release may include information that constitutes “forward-looking statements” made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Statements that describe the Company’s business strategy, goals, prospects, opportunities, outlook, plans or intentions are also forward-looking statements. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties set forth in the company’s periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC’s website at http://www.sec.gov, and at the company’s website at http://www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.

Cirrus Logic (CRUS) Announces Preliminary Q3 Revenue Increases 49 Percent Year Over Year

Jan. 11, 2010 (Business Wire) — Cirrus Logic Inc. (Nasdaq: CRUS) today announced that the company expects net revenue for the third fiscal quarter, which ended on Dec. 26, 2009, to be up 49 percent year over year, and up 17 percent sequentially to approximately $65 million, an increase from the previous guidance of $58 million to $62 million. The increase over forecasted revenue was driven by stronger than anticipated demand for a broad range of audio products, as well as modest improvement in demand for energy products.

The company expects gross margin to be approximately 54 percent. Combined R&D and SG&A expenses are expected to be approximately $24.3 million and include an estimated $1.8 million in share-based compensation and amortization of acquisition-related intangible expenses, as well as $400,000 in favorable facilities related credits.

“We continued to experience strong growth in the December quarter as revenue from new products maintained its momentum and we had increased demand from our customers for a broad mix of both our audio and energy products,” said Jason Rhode, president and chief executive officer of Cirrus Logic. “Building on this momentum, we believe that revenue for the March quarter will exceed $53 million, which would represent greater than 58 percent year over year growth. We will release full guidance for the March quarter on Jan. 28.”

Cirrus Logic will hold its quarterly conference call to discuss third quarter, fiscal year 2010 financial results on Thursday, Jan. 28, 2010, at 10:30 a.m. EST. Cirrus Logic will release the company’s financial results at approximately 8:00 a.m. EST on the same day.

To listen to the live conference call, dial 480-629-9866, or toll-free at 888-549-7750 (Conference ID: 4198207) by 10:20 a.m. EST on Jan. 28. A replay of the conference call will be available beginning one hour following the completion of the call, until Feb. 4, 2010. To access the recording, dial 303-590-3030, or toll-free at 800-406-7325 (Conference ID: 4198207). Additionally, the conference call will be webcast live through the Investor Relations page of the company’s website at www.cirrus.com.

Cirrus Logic also announced it will present at the 12^th Annual Needham Growth Stock Conference on Thursday, Jan. 14, 2010, at 4:30 p.m. EST at The New York Palace Hotel in New York City. A live webcast of the presentation will be available on the Investor Relations page of the company’s website.

Cirrus Logic, Inc.

Cirrus Logic develops high-precision, analog and mixed-signal integrated circuits for a broad range of innovative customers. Building on its diverse analog and signal-processing patent portfolio, Cirrus Logic delivers highly optimized products for a variety of audio and energy-related applications. The company operates from headquarters in Austin, Texas, with offices in Tucson, Ariz., Europe, Japan and Asia. More information about Cirrus Logic is available at www.cirrus.com.

Safe Harbor Statement

Except for historical information contained herein, the matters set forth in this news release contain forward-looking statements, including our estimates of third quarter fiscal year 2010 revenue, gross margin, combined research and development and selling, and general and administrative expense levels as well as our estimates of fourth quarter fiscal year 2010 revenue. In some cases, forward-looking statements are identified by words such as “expect,” “anticipate,” “target,” “project,” “believe,” “goals,” “opportunity,” “estimates,” and “intend,” variations of these types of words and similar expressions are intended to identify these forward-looking statements. In addition, any statements that refer to our plans, expectations, strategies or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, the following: overall economic pressures and general market and economic conditions; overall conditions in the semiconductor market; the level of orders and shipments during the fourth quarter of fiscal year 2010, as well as customer cancellations of orders, or the failure to place orders consistent with forecasts; the loss of a key customer; pricing pressures; and the risk factors listed in our Form 10-K for the year ended March 28, 2009, and in our other filings with the Securities and Exchange Commission, which are available at www.sec.gov. The foregoing information concerning our business outlook represents our outlook as of the date of this news release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new developments or otherwise.

Zareba Systems, Inc. (ZRBA) Announces Merger Agreement with Woodstream Corporation

Jan. 11, 2010 (Business Wire) — Zareba Systems, Inc. (NASDAQ:ZRBA) announced today that it has signed a definitive agreement to merge with a subsidiary of Woodstream Corporation, a Pennsylvania corporation. Woodstream is majority owned by private equity firms Brockway Moran & Partners, Inc. and Code Hennessy & Simmons LLC.

Under the terms of the agreement, a newly-formed subsidiary of Woodstream will merge with and into Zareba, Zareba will become a wholly-owned subsidiary of Woodstream, and Zareba shareholders will receive $9.00 in cash for each outstanding share of Zareba common stock. This price represents a premium of approximately 100% over the closing price of Zareba stock on January 11, 2010. Zareba’s board of directors and a special committee of Zareba’s disinterested directors have unanimously approved the agreement and the merger. The merger is expected to be completed in the first half of 2010 and is subject to Zareba shareholder approval and other customary closing conditions. A special meeting of Zareba shareholders will be announced following preparation and filing of proxy materials with the Securities and Exchange Commission.

“Our board thoroughly explored strategic alternatives for enhancing shareholder value and determined that this transaction with Woodstream represents an excellent value to our shareholders,” stated Zareba President and Chief Executive Officer Dale Nordquist. “Furthermore, our complementary product offerings and market strengths will also result in the substantial utilization of our existing operations and employees going forward.”

“Zareba’s and Woodstream’s Fi-Shock product offerings are highly complementary and when combined will result in an impressive portfolio of products, brands and intellectual property” stated Woodstream President and Chief Executive Officer Harry E. Whaley. “Zareba’s operations will significantly enhance our operating capabilities and allow us to better serve the needs of our customers around the world.”

Greene Holcomb & Fisher LLC acted as financial advisor, and Fredrikson & Byron, P.A. served as legal advisor, to Zareba. William Blair & Company LLC acted as financial advisor, and Faegre & Benson LLP served as legal advisor, to Woodstream.

About Zareba Systems, Inc.

Zareba Systems, Inc., a Minnesota corporation since 1960, is the world’s leading manufacturer of electronic perimeter fence and security systems for animal and access control. The Company’s corporate headquarters is located in Minneapolis, with manufacturing facilities in Ellendale, Minn. Its Zareba Systems Europe subsidiary owns Rutland Electric Fencing Co., the largest manufacturer of electric fencing products in the United Kingdom. The corporate web site is located at www.ZarebaSystemsInc.com.

About Woodstream Corporation

Woodstream Corporation, a Pennsylvania corporation since 1902, is a designer, manufacturer and marketer of a broad range of branded consumer products with facilities in Canada, Colorado, Missouri, Pennsylvania, Tennessee and China. The Company’s product portfolio includes wild bird feeders, organic pest controls, rodent and wild animal control equipment, lawn & garden décor products and animal training and containment products marketed under a variety of brands including Victor®, Fi-Shock®, Safer Brand®, Perky Pet®, Mosquito Magnet® and Havahart®. Woodstream’s products are sold at more than 100,000 retail locations throughout the United States and internationally. The corporate web site is located at www.woodstreamcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements also include the assumptions underlying or relating to any of the foregoing statements. Such forward-looking statements are based upon current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this press release include statements about future financial and operating results and the proposed transaction. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. For example, if Zareba does not receive required shareholder approval or fails to satisfy other conditions to closing, the transaction will not be consummated. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: failure of the Zareba shareholders to approve the proposed merger; and failure of other conditions to closing of the merger to be satisfied. All forward-looking statements included in this press release are based on information available to Zareba on the date hereof. Zareba undertakes no obligation (and expressly disclaims any such obligation) to update forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to update reasons why actual results could differ from those anticipated in such forward-looking statements.

Additional Information

Zareba intends to file a proxy statement and other relevant documents concerning the proposed transaction with the SEC. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANIES AND THE PROPOSED TRANSACTION.

Zareba’s officers and directors may be deemed, under SEC rules, to be participants in the solicitation of proxies from the shareholders of Zareba with respect to the transactions contemplated by the merger agreement. Information regarding Zareba’s directors and executive officers is contained in Zareba’s Annual Report on Forms 10-K and 10-K/A for the fiscal year ended June 30, 2009, which are filed with the SEC. More detailed information regarding the identity of potential participants in the solicitation, and their direct or indirect interests, by securities holdings or otherwise, which interests may be different from those of Zareba’s shareholders generally, will be set forth in the proxy statement and other materials to be filed with SEC in connection with the proposed transaction. Each of these documents is, or will be, available free of charge at the website maintained by the SEC at www.sec.gov, and at Zareba’s website, www.ZarebaSystemsInc.com.

Hillenbrand to Acquire K-Tron International (KTII)

BATESVILLE, Indiana and PITMAN, New Jersey, January 11

Tuesday Morning Corp. (TUES) Announces Second Quarter Fiscal 2010 Sales

DALLAS, Jan. 11, 2010 (GLOBE NEWSWIRE) — Tuesday Morning Corporation (Nasdaq:TUES) today reported net sales for the second quarter ended December 31, 2009 were $289.6 million compared to $272.7 million for the quarter ended December 31, 2008, an increase of 6.2%. Comparable store sales for the quarter ended December 31, 2009 increased by 5.1% comprised of a 5.3% increase in traffic and a 0.2% decrease in ticket. For the six-month period ended December 31, 2009, net sales were $455.5 million compared to $446.1 million for the same time last year. Comparable store sales for the six-month period ended December 31, 2009 increased 0.8%.

Based upon the results of the quarter, the Company currently expects diluted earnings per share for the second quarter to be in the range of $0.40 to $0.43. Diluted earnings per share were $0.31 for the quarter ended December 31, 2008. Based upon the above results, we have revised our guidance for the full fiscal year ending June 30, 2010 as follows:

 Net Sales:                   $805 million to $815 million
 Comparable store sales:      Negative low single digits to flat
 Diluted earnings per share:  $0.06 to $0.10
 Capital expenditures:        $21 million
 Decrease in store count:     (7)

Kathleen Mason, President and Chief Executive Officer, stated, “We were pleased with the increase in traffic during the holiday selling season in the midst of a highly competitive retail environment. We increased our cash position from the prior year, achieved higher sales on reduced inventory, and eliminated debt. All of these factors contributed to improving an already strong balance sheet.”

The Company expects to release second quarter financial results on January 26, 2010.

About Tuesday Morning

Tuesday Morning is a leading closeout retailer of upscale, decorative home accessories, housewares and famous-maker gifts in the United States. The Company opened its first store in 1974 and currently operates 858 stores in 43 states. Tuesday Morning is nationally known for bringing its more than 9.0 million loyal customers a unique treasure hunt of high-end, first quality, brand name merchandise…never seconds or irregulars…at prices well below those of department and specialty stores and catalogues.

This press release contains forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, estimates and projections. Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend” and similar words, although some forward-looking statements are expressed differently. You should carefully consider statements that contain these words because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our future results of operations, our future financial positions, and our business outlook or state other “forward-looking” information.

Reference is hereby made to “Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2009 for examples of risks, uncertainties and events that could cause our actual results to differ materially from the expectations expressed in our forward-looking statements. These risks, uncertainties and events also include, but are not limited to, the following: uncertainties regarding our ability to open stores in new and existing markets and operate these stores on a profitable basis; conditions affecting consumer spending and the impact, depth and duration of the current economic recession; inclement weather; changes in our merchandise mix; timing and type of sales events, promotional activities and other advertising; increased or new competition; loss or departure of one or more members of our senior management, or experienced buying and management personnel; an increase in the cost or a disruption in the flow of our products; seasonal and quarterly fluctuations; fluctuations in our comparable store results; our ability to operate in highly competitive markets and to compete effectively; our ability to operate information systems and implement new technologies effectively; our ability to generate strong cash flows from our operations; our ability to maintain internal control over financial reporting; our ability to continue obtaining funding from external sources; our ability to anticipate and respond in a timely manner to changing consumer demands and preferences; and our ability to generate strong holiday season sales. The forward-looking statements made in this press release relate only to events as of the date on which the statements were made. We undertake no obligations to update our forward-looking statements to reflect events and circumstances after the date on which the statements were made or to reflect the occurrence of unanticipated events.

MAP Pharmaceuticals (MAPP) Announces FDA will not Require a Second Pivotal Efficacy Study

MOUNTAIN VIEW, Calif. /PRNewswire-FirstCall/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company’s LEVADEX™ new drug application (NDA) submission for the acute treatment of migraine. The Company announced in that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.

“We are pleased that the LEVADEX program can move forward without a second pivotal efficacy study; this news underscores our confidence in the program and allows us to focus our resources and efforts on completing our remaining clinical studies to support our NDA submission,” said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. “We believe that LEVADEX has the potential to provide rapid and sustained relief of migraine symptoms to many of the approximately 30 million migraine sufferers in the U.S., including many who are not helped by currently available migraine therapies and we are committed to rapidly moving this program forward.”

The remaining clinical studies include the ongoing 12 month open-label safety extension of the FREEDOM-301 study, a pharmacokinetic (PK) study and a pharmacodynamic (PD) study. The Company anticipates that patients in these studies will complete treatment in 2010.

The goal of the long-term safety extension is to evaluate overall safety, including pulmonary and cardiovascular safety, of LEVADEX in 300 patients for six months and 150 patients, including asthmatics, for 12 months. The study is being conducted under a Special Protocol Assessment with the FDA. As previously announced, as of , more than 400 patients had completed at least six months of treatment and over 7,800 headaches had been treated, with no drug-related serious adverse events reported.

The PK study will compare the safety, PK and metabolic profiles of LEVADEX with IV dihydroergotamine (DHE) in smokers. The PD study will evaluate pulmonary artery pressure in healthy volunteers.

About LEVADEX™

LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company’s proprietary TEMPO® inhaler. In the Phase 3 FREEDOM-301 trial, LEVADEX met all four co-primary endpoints at two hours: pain relief (p<0.0001); phonophobia free (p<0.0001); photophobia free (p<0.0001); and nausea free (p=0.02). Data from this Phase 3 trial show the potential for LEVADEX to be effective in treating acute migraine as well as a broad spectrum of migraine subpopulations that are often difficult to treat with current therapies, including triptans. For example in this trial, patients with allodynia, menstrual migraine, migraine with nausea and vomiting, severe migraine and those treating late in their migraine cycle responded well to LEVADEX.

LEVADEX is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action, sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the efficacy portion of the FREEDOM-301 trial, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraines, while minimizing the side effects commonly seen with DHE and other currently available medicines.

About Migraine

Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals’ LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company’s business, including, without limitation, risks and uncertainties relating to the enrollment, conduct and completion of clinical trials, failure to achieve favorable clinical outcomes and to have the company’s LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals’ results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended , as amended, and its Quarterly Report on Form 10-Q for the quarter ended , available at http://edgar.sec.gov.

Energy XXI (EXXI) Announces Major Discovery at Davy Jones Ultra-Deep Well

HOUSTON, Jan. 11, 2010 (GLOBE NEWSWIRE) — Energy XXI (Bermuda) Limited (Nasdaq:EXXI) (LSE:EXXI) today announced a discovery on its Davy Jones ultra-deep prospect located on South Marsh Island Block 230 in approximately 20 feet of water. The well has been drilled to 28,263 feet and has been logged with pipe-conveyed wireline logs to 28,134 feet. The wireline log results indicated a total of 135 net feet of hydrocarbon-bearing sands in four zones in the Wilcox section of the Eocene/Paleocene. All of the zones were full to base, with two of the zones containing a combined 90 net feet. The Eocene/Paleocene (Wilcox) suite of sands logged below 27,300 feet appears to be of exceptional quality. Flow testing will be required to confirm the ultimate hydrocarbon flow rates from the four separate zones. The resistivity log obtained on January 10th was the last data needed to confirm hydrocarbons in South Marsh Island Block 230. Drilling will resume to deepen the well to a proposed depth of 29,000 feet to test additional objectives.

“The Davy Jones discovery verifies the ultra-deep potential of the Gulf of Mexico shelf and opens this horizon as a major exploration frontier,” Energy XXI Chairman and CEO John Schiller said. “Our partner McMoRan has done an outstanding job leading this extraordinary exploration effort, and we look forward to an active and exciting drilling program to further define and expand the ultra-deep shelf play.”

Energy XXI, through a joint venture Area of Mutual Interest with McMoRan, has the option to continue participating in further exploration within the ultra-deep shelf play below the salt weld. Prospects on this acreage have multi-Tcfe gross unrisked potentials and target objective sections on the shelf in the Miocene and older age sections that have been correlated to those productive sections seen in deepwater discoveries made by other industry participants.

Energy XXI is funding 14.1 percent of the exploratory costs to earn a 15.8 percent working interest and 12.6 percent net revenue interest at Davy Jones. Other working interest owners in Davy Jones include: McMoRan Exploration Co. (NYSE:MMR), with 32.7 percent; Plains Exploration & Production Company (NYSE:PXP), with 27.7 percent; Nippon Oil Exploration USA Limited, with 12 percent; and W.A. “Tex” Moncrief, Jr., with 8.8 percent.

Forward-Looking Statements

All statements included in this release relating to future plans, projects, events or conditions and all other statements other than statements of historical fact included in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon current expectations and are subject to a number of risks, uncertainties and assumptions, including changes in long-term oil and gas prices or other market conditions affecting the oil and gas industry, reservoir performance, the outcome of commercial negotiations and changes in technical or operating conditions, among others, that could cause actual results, including project plans and related expenditures and resource recoveries, to differ materially from those described in the forward-looking statements. Energy XXI assumes no obligation and expressly disclaims any duty to update the information contained herein except as required by law.

Competent Person Disclosure

The technical information contained in this announcement relating to operations adheres to the standard set by the Society of Petroleum Engineers. Tom O’Donnell, Vice President of Corporate Development, a registered Petroleum Engineer, is the qualified person who has reviewed and approved the technical information contained in this announcement.

About the Company

Energy XXI is an independent oil and natural gas exploration and production company whose growth strategy emphasizes acquisitions, enhanced by its value-added organic drilling program. The company’s properties are located in the U.S. Gulf of Mexico waters and the Gulf Coast onshore. Collins Stewart Europe Limited and Macquarie Capital (Europe) Limited are Energy XXI listing brokers in the United Kingdom. To learn more, visit the Energy XXI website at www.energyXXI.com.

The Energy XXI logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3587

Glossary

Barrel — unit of measure for oil and petroleum products, equivalent to 42 U.S. gallons.

BOE — barrels of oil equivalent, used to equate natural gas volumes to liquid barrels at a general conversion rate of 6,000 cubic feet of gas per barrel.

Field — an area consisting of a single reservoir or multiple reservoirs all grouped on, or related to, the same individual geological structural feature or stratigraphic condition. The field name refers to the surface area, although it may refer to both the surface and the underground productive formations.

MCF — thousand cubic feet of gas.

MMBOE — million barrels of oil equivalent.

MMCF — million cubic feet of gas.

PV10 — the estimated present value of the resource, discounted at a 10 percent annual rate.

Tcfe — trillion cubic feet equivalent.

InvestorSoup Initiates Independent Research Coverage for Pacific Ethanol Inc. (PEIX)

DALLAS, Jan. 11, 2010 (GLOBE NEWSWIRE) — InvestorSoup.com announces an investment report featuring Pacific Ethanol Incorporated (Nasdaq:PEIX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.investorsoup.com/lp/PEIX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

Pacific Ethanol Inc. (PEIX) produces and markets cellulose-based ethanol and bio-diesel in the United States. The Company intends to take advantage of the Energy Independence and Security Act of 2007 which mandates the use of 36 billion gallons of ethanol in the United States by 2022.

Message Board Search for PEIX: http://www.boardcentral.com/boards/PEIX

In the report, the analyst notes:

“Global production remains a key driver of fossil fuels prices, with production in both OECD and ASEAN countries weighing heavily on total world production outputs. Most economists expect a rebound in durable goods production in Asia, especially China. China’s real GDP growth is expected to reach 8% in 2010, officially, while GDP growth in the OECD countries is anticipated to be flat or rise slightly. Since the demand for energy correlates strongly with overall economic activity, oil and natural gas prices may continue higher as excess inventories are depleted and diminishing new supplies struggle to satisfy increasing demand beginning early in 2010, according to the Energy Information Administration (EIA). The condition of growing GDP dependent on increasing demand for a increasingly more expensive energy source is very bullish for the demand for biofuels.

“On January 6, the Company announced that production has resumed at its southern Idaho ethanol plant following a nearly year-long hiatus and a federal bankruptcy protection filing in May 2009 of the Company’s subsidiary that runs the plant. The Company said that it intends to add 35 workers at the plant built to process as much as 60 million gallons of ethanol per year.”

To read the entire report visit: http://www.investorsoup.com/lp/PEIX

See what investors say about PEIX at penny stock forum.

InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com

InvestorSoup.com Disclosure

InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.

Adeona (AEN) Announces Additional $860,000 Grant for Oral Estriol Multiple Sclerosis Clinical Trial

ANN ARBOR, MI–(Marketwire – 01/08/10) – Adeona Pharmaceuticals, Inc., (AMEX:AEN – News), a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population, announced today that the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate being conducted by Dr. Rhonda Voskuhl, Director, UCLA Multiple Sclerosis Program, UCLA Dept. of Neurology has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at sixteen sites in the US and will enroll up to 150 female Multiple Sclerosis (MS) patients. Investigators will administer Trimesta along with glatimer acetate (Copaxone�), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the National MS Society’s Southern California chapter, with support from the National Institutes of Health (NIH).

According to Dr. Voskuhl, “This additional funding has already had a very positive impact on our trial. It has greatly increased the rate of enrollment by supporting the addition of 9 more clinical sites, bringing the total up to 16 sites across the US. We were extremely pleased that our trial was deemed important enough to be supplemented with these additional funds.”

Previous Phase II Clinical Trial Results in Relapsing Remitting Multiple Sclerosis

Trimesta (oral estriol) has previously completed an initial 22-month, single-agent, crossover Phase I/II clinical trial in the US for the treatment of MS in relapsing remitting patients, with highly encouraging results. The results showed the total volume and number of enhancing pathogenic myelin lesions (established neuroimaging measurements of disease activity in MS) decreased during the treatment period as compared to a six-month pretreatment baseline period. The median total enhancing lesion volumes decreased by 79 percent (p=0.02) and the number of lesions decreased by 82 percent (p=0.09) within the first three months of treatment with Trimesta. Following a six-month drug holiday during which the patients weren’t on any drug therapies, Trimesta therapy was reinitiated during a four-month retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88 percent (p=0.008) and a decrease in the number of lesions by 48 percent (p=0.04) compared with original baseline scores (1),(2).

Improvement in Cognitive Testing Scores

During the prior Phase I/II clinical trial, a 14-percent improvement in Paced Auditory Serial Addition Test (“PASAT”) cognitive testing scores (p=0.04) was also observed in the MS patients at six months of therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS. The PASAT scores were expressed as a mean percent change from baseline and were significantly improved in the relapsing-remitting group.

About the Trimesta Phase II/III Study

In the current phase II/III study, Trimesta is being given orally once-a-day versus placebo to 150 female relapsing-remitting MS patients in combination with a standard of care background therapy, subcutaneously injected glatimer acetate. The primary endpoint for the study will evaluate effects of the treatment combination on relapse rates at two years with a one year interim analysis using standard clinical measures of MS disability as well as secondary endpoints of magnetic resonance imaging measurements of brain lesion and effects on cognition. The study is approaching 50% enrollment with the rate of enrollment benefiting significantly from the expansion of clinical sites.

About Trimesta

Trimesta is an orally active, immunomodulatory and anti-inflammatory molecule which has been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes, but which has never been introduced in North America. Estriol, the active ingredient in Trimesta, is a weak estrogenic-based molecule that is produced in the placenta by women during pregnancy. Estriol is considered to play an important role in the immunologic privilege offered to the fetus during pregnancy, and is also thought to be responsible for the spontaneous remission of Th1-mediated autoimmune diseases of women (such as multiple sclerosis and rheumatoid arthritis) during pregnancy, especially during the third trimester. Adeona has an exclusive worldwide license from UCLA to issued and pending patents invented by Dr. Voskuhl including U.S. Patent 6,936,599 covering estriol’s use for MS. While currently marketed therapies for MS sell billions of dollars annually, all require frequent injections and currently is no FDA-approved oral therapy for the treatment of MS.

About Adeona Pharmaceuticals, Inc.

Adeona Pharmaceuticals, Inc. (AMEX:AEN – News) is a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that these conditions may contribute to the progression of debilitating degenerative diseases, including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Using Adeona’s proprietary, modified oral zinc delivery technologies, Adeona is preparing to initiate the first clinical trial of oral zinc therapy for the once-a-day dietary management of AD and MCI. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis. For further information, please visit www.adeonapharma.com.

This release includes forward-looking statements on Adeona’s current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding designing additional clinical trials for its oral zinc therapies, dnaJP1, Zinthionein, Zinthionein ZC, flupirtine, or Trimesta. Adeona is at an early stage of development and may not ever have any products that generate significant revenue. Adeona’s Hartlab subsidiary is generating modest revenues and its future success will likely depend upon its ability to successfully introduce and market new specialty diagnostic assays to generate additional revenues. Important factors that could cause actual results to differ materially from those reflected in Adeona’s forward-looking statements include, among others, a failure of Adeona’s product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company’s products or to comply with ongoing regulatory requirements, regulatory limitations relating to the company’s ability to promote or commercialize its products for awareness, prevention, diagnosis or treatment of zinc deficiency and chronic copper toxicity, a lack of acceptance of Adeona’s product candidates in the marketplace, a failure of the company to become or remain profitable, that we will continue to meet the continued listing requirements of the American Stock Exchange (which, unlike other exchanges, does not require us to maintain any minimum bid price with respect our stock but does require us to maintain a minimum of $6 million in stockholders’ equity during the current year, for example), our inability to obtain the capital necessary to fund the company’s research and development activities, a loss of any of the company’s key scientists or management personnel, and other factors described in Adeona’s report on Form 10-K for the year ended December 31, 2008, Forms 10-Q for quarters ending in 2009 and any other filings with the SEC. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Copaxone� is a registered trademark of Teva Neurosciences, Inc.

WorldHeart (WHRT) Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD

SALT LAKE CITY /PRNewswire-FirstCall/ — World Heart Corporation (“WorldHeart”; Nasdaq: WHRT), a developer of mechanical circulatory systems, announced today that it has received unconditional approval from the U.S. Food and Drug Administration (“FDA”) for the bridge-to-transplant (“BTT”) study of the Levacor Ventricular Assist Device (“VAD”).  Study enrollment will encompass 160 subjects, a reduction from the approximately 200 subjects of the original statistical plan.  As previously announced, the BTT study will begin initially at ten clinical sites.

“We are especially pleased to receive unconditional approval for the Levacor BTT clinical trial in conjunction with a significant reduction in total sample size,” notes Mr. J. Alex Martin, WorldHeart’s President and Chief Executive Officer.  “Since receiving the FDA’s conditional approval, we have been actively working with involved physicians, their hospital administrations and Institutional Review Boards (IRBs) to attain individual center readiness.  We have also been providing in-depth surgical and technical training and expect to have our first implant this quarter.”

As described by Mr. Jal S. Jassawalla, WorldHeart’s Executive Vice President and Chief Technology Officer, “The Levacor VAD is the only fully magnetically levitated, bearingless, implantable centrifugal pump to move into clinical trial.”  By using magnetic levitation to fully suspend a spinning rotor, the Levacor VAD’s only moving part, the pump is designed to eliminate wear and to provide unobstructed clearances for blood flow across a wide range of operation.  Mr. Jassawalla said, “We are enthusiastic about the potential for this technology and look forward to demonstrating its safety and efficacy in the upcoming trial.”

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. World Heart’s registered office is in Delaware, USA.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to WorldHeart’s bridge-to-transplant clinical study of the Levacor Ventricular Assist Device, strategic direction, increase in shareholder value, access to investment capital, its clinical development programs and the product pipeline, and the growth of WorldHeart’s overall business, as well as other statements that can be identified by the use of forward-looking language, such as “believes,” “feels,” “expects,” “may,” “will,” “should,” “seeks,” “plans,” “anticipates,” or “intends” or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart’s need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart’s products; and other risks detailed in WorldHeart’s filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K  for the year ended and its Quarterly Reports on Form 10-Q for the quarters ended and .

Zargis Cardioscan Cleared for Sale in Canada

STAMFORD, Conn. — Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that Health Canada, the Canadian equivalent of the U.S. FDA, has cleared the Zargis Cardioscan™ device for sale in Canada.

The Cardioscan heart sound analysis software connects wirelessly to a Bluetooth®-enabled electronic stethoscope and is designed to help physicians analyze cardiac sounds for the identification and classification of suspected heart murmurs. As previously announced, Zargis Medical was a co-recipient of Popular Science magazine’s 2009 “Innovation of the Year” award for Cardioscan.

With 62,000 physicians treating a population of nearly 34 million people, Canada represents a significant market for Zargis. Furthermore, Cardioscan’s optional telemedicine capabilities are well suited for the Canadian healthcare system, which has embraced telemedicine as a core initiative. The introduction of Cardioscan into this market will provide benefits during face-to-face patient encounters and allow healthcare providers to extend the use of auscultation (listening with a stethoscope) to situations and environments where face-to-face encounters are not always feasible.

“We’ve been seeing increasing interest among the Canadian medical community in Cardioscan and its telemedicine functionality, which is predictable given Canada’s geography and the nature of its population distribution,” stated Zargis CEO John Kallassy.

This clearance allows Zargis to immediately begin marketing Cardioscan and the accompanying stethoscope in Canada. To order or inquire about distribution opportunities visit www.zargis.com.

About Zargis Medical Corp.

Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus Corp. (Nasdaq: SPDE), and both 3M Company (NYSE: MMM) and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.

For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or phodge@zargis.com, or visit the following Web sites: www.zargis.com and www.speedus.com.

Statements contained herein that are not historical facts, including but not limited to statements about the Company’s product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company’s sales, marketing and support efforts.

Immunomedics (IMMU) – Potential Lupus Drug Gains U.S. Patent

MORRIS PLAINS, N.J., Jan. 8, 2010 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its patent for “Immunotherapy of autoimmune disorders using antibodies which target B-cells” has been issued as U.S. patent no. 7,641,901. The patent covers the use of monoclonal antibodies that bind to the CD22 antigen on B-lymphocytes for treating autoimmune disorders. The allowed claims cover the use of epratuzumab, the Company’s proprietary humanized anti-CD22 monoclonal antibody, and other anti-CD22 antibodies, alone and in combination with other therapeutics, such as antibodies, cytokines, or drugs, for the treatment of a wide range of autoimmune diseases that include systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, multiple sclerosis, myasthenia gravis, diabetes mellitus, and ulcerative colitis.

“This patent further strengthens our intellectual property protection of epratuzumab, for the treatment of autoimmune diseases,” commented Cynthia L. Sullivan, President and CEO. “Our partner, UCB, has recently reported encouraging top-line results from their Phase IIb study of epratuzumab in lupus and is planning to initiate a Phase III program for 2010,” added Ms. Sullivan.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 141 patents issued in the United States and more than 300 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Luna Innovations (LUNA) and Intuitive Surgical (ISRG) Expand Relationship

Jan. 8, 2010 (Business Wire) — Luna Innovations Incorporated (NASDAQ: LUNA) announced today that it will be extending its development and supply agreement with Intuitive Surgical, Inc. (NASDAQ: ISRG) to continue integrating Luna’s shape sensing technology into Intuitive’s products.

In June 2007, Luna and Intuitive entered into a multi-year development and supply agreement in which Luna would supply its fiber optic based shape sensing system for integration into Intuitive’s medical robotics products and license its shape sensing technology to Intuitive for this purpose. Intuitive Surgical is the global technology leader in robotic-assisted minimally invasive surgery and its products include the da Vinci® Surgical System. Luna has successfully achieved the expectations of the development work in the original agreement, which concluded in December of 2009.

Luna and Intuitive will be extending their development and supply agreement to further develop Luna’s technology for its products.

“This new agreement with Intuitive Surgical will continue Luna’s relationship with the leader in the medical robotics market and further demonstrates the potential of our technology and intellectual property,” stated Kent Murphy, Luna’s Chairman and Chief Executive Officer. “It has been a great relationship over the past thirty months, and it is extremely rewarding to know that Luna’s technology will be assisting in complex minimally invasive surgery in the pursuit of delivering the best outcome for patients.”

“We continue to view Luna as a strong technology partner in the area of advanced shape sensing and position tracking systems,” said Dave Rosa, Intuitive’s Vice President of New Product Development. “Our development with Luna is progressing well and Intuitive remains committed to our joint project.”

Luna’s exclusive shape sensing system tracks the position of an optical fiber along its entire length, providing real-time measurements that can assist surgeons in navigating through the body. This technology could be particularly helpful in certain minimally invasive surgical techniques because of the need to track the position of medical instruments in the patient, using optical fibers as thin as a human hair to provide sensing and feedback as the nervous system does for the human body.

Luna will host a conference call with investors on Jan. 11, 2010, at 1:30 p.m. (EST) to discuss this and other announcements upon the company’s emergence from bankruptcy. The investor conference call will be available via live webcast on the Luna Innovations’ website at http://www.lunainnovations.com/ under the tab “Investor Relations.” To participate by telephone, the domestic dial-in number is 1.800.299.7928 and the international dial-in number is 1.617.614.3926. The participant access code is 97312544. Investors are advised to dial in at least five minutes prior to the call to register. The webcast will be archived on the company’s website under “Webcasts and Presentations” for 30 days following the conference call.

About Luna Innovations:

Luna Innovations Incorporated (www.lunainnovations.com) is focused on sensing and instrumentation, and pharmaceutical nanomedicines. Luna develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. The company’s products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.

Forward-Looking Statements:

This release includes information that constitutes “forward-looking statements” made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements regarding, but not limited to the potential of Luna’s technology and intellectual property, any possible improvements to medical surgeries and/or medical outcomes, and the future relationship between Luna and Intuitive and incorporation of Luna’s technology into Intuitive’s products. Statements that describe the Company’s business strategy, goals, prospects, opportunities, outlook, plans or intentions are also forward looking statements. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including technical and scientific difficulties, complications or difficulties in improving medical surgeries and/or outcomes, market forces in the medical industry, and issues that might arise in any particular business relationship, and risks and uncertainties set forth in the company’s periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC’s website at http://www.sec.gov, and at the company’s website at http://www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.

Versar (VSR) Awarded $7 Million Contract by U.S. Environmental Protection Agency

Jan. 7, 2010 (Business Wire) — Versar, Inc. (NYSE Amex: VSR) announced today that the Office of Pollution Prevention and Toxics (OPPT) of the U.S. Environmental Protection Agency (EPA) has awarded Versar a 5-year, $7 million contract for exposure assessments for toxic substances. This contract is one of five major EPA contracts currently managed by Versar’s Exposure and Risk Assessment Division, and will continue Versar’s 30 years of support for the EPA’s toxic substances exposure and risk assessment programs.

Under this contract, Versar will conduct exposure and risk assessments for toxic chemicals, develop data analysis models and databases, and refine exposure assessment methodologies in support of OPPT’s review of new and existing chemicals.

Dr. Ted Prociv, President and CEO of Versar, said, “Versar continues to be recognized as a leader in risk and exposure assessment of toxic and other chemical substances. These programs are among the EPA’s highest priorities to better characterize chemical exposures and risks to our communities. Versar brings innovative approaches and rigorous scientific analysis forward to support the EPA’s programs that ensure the safety of all our citizens.”

VERSAR, INC., headquartered in Springfield, VA, is a publicly held international professional services firm supporting government and industry in national defense/homeland defense programs, environmental health and safety and infrastructure revitalization. VERSAR operates a number of web sites, including the corporate Web sites, http://www.versar.com, http://www.homelanddefense.com, http://www.geomet.com; http://www.viap.com; http://www.dtaps.com; and www.ppsgb.com.

This press release contains forward-looking information. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described herein and in Versar’s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended June 26, 2009. The forward-looking statements are made as of the date hereof and Versar does not undertake to update its forward-looking statements.

ZixCorp’s (ZIXI) Preliminary Results for Fourth Quarter 2009 Point to Best Quarter in Company History

DALLAS, Jan. 6

COMSYS IT Partners, Inc. (CITP) Revises Fourth Quarter 2009 Guidance Upward

Jan. 6, 2010 (Business Wire) — COMSYS IT Partners, Inc. (NASDAQ:CITP), a leading provider of information technology staffing and consulting services, today revised its guidance upward for the fourth quarter of 2009.

The Company now expects to report revenue in a range of $170 million to $175 million for the fourth quarter and net income in the range of $5.3 million to $6.4 million, or approximately $0.25 to $0.30 per diluted share, up on a comparable basis from the Company’s earlier guidance of revenue in a range of $161 million to $166 million and net income in the range of $2.5 million to $3.6 million, or approximately $0.13 to $0.18 per diluted share.

For the year ended January 3, 2010, the Company now expects to report revenue in the range of $647 million to $652 million, and net income before restructuring charges in the range of $12.9 million to $14.0 million, or approximately $0.62 to $0.67 per diluted share, also up on a comparable basis from the previous full year guidance. The revised estimates are also based on an effective tax rate of approximately 6.4%.

Like our prior guidance, the revised net income and earnings per share estimates above exclude an expected reversal of a portion of restructuring expense previously recognized related to our Washington DC area lease, as well as any potential effects of our quarterly review of the recoverability of our deferred tax assets.

“The strengthening activity levels that we reported on in late October have continued through November and December,” said Larry L. Enterline, COMSYS Chief Executive Officer, “and we also expect to report a sequential increase in gross margins due to higher margins in our core staffing business and increased fee income in TAPFIN. As a result, earnings per share should be well above our previous range notwithstanding our continued spending in the fourth quarter on the business initiatives we have commented on throughout the year. Cash flow in the fourth quarter was also better than expected and we ended the year with less than $40 million of debt.”

About COMSYS IT Partners

COMSYS IT Partners, Inc. (NASDAQ: CITP) is a leading IT services company with 52 offices across the U.S. and offices in Puerto Rico, Canada and the U.K. COMSYS service offerings include contingent and direct hire placement of IT professionals and a wide range of technical services and solutions addressing requirements across the enterprise. TAPFIN Process Solutions delivers critical management solutions across the resource spectrum from contingent workers to outsourced services.

Forward-looking Statements

Certain information contained in this press release may be deemed forward-looking statements regarding events and financial trends that could affect our plans, objectives, future operating results, financial condition, performance and business. These statements may be identified by words such as “estimate,” “forecast,” “plan,” “intend,” “believe,” “should,” “expect,” “anticipate,” or variations or negatives thereof, or by similar or comparable words or phrases. These forward-looking statements are largely based on our expectations and beliefs concerning future events, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, including:

• economic declines that affect our business, including our profitability, liquidity or the ability to comply with applicable loan covenants;
• the financial stability of our lenders and their ability to honor their commitments related to our credit agreements;
• regulatory changes that impose additional regulations or licensing requirements in such a manner as to increase our costs of doing business or restrict access to qualified technology workers;
• the risk of increased tax rates;
• adverse changes in credit and capital markets conditions that may affect our ability to obtain financing or refinancing on favorable terms or that may warrant changes to existing credit terms;
• the financial stability of our customers and other business partners and their ability to pay their outstanding obligations or provide committed services;
• changes in levels of unemployment and other economic conditions in the United States, or in particular regions or industries;
• the impact of changes in demand for our services or competitive pressures on our ability to maintain or improve our operating margins, including pricing pressures;
• the risk in an uncertain economic environment of increased incidences of employment disputes, employment litigation and workers’ compensation claims;
• our success in attracting, training, retaining and motivating billable consultants and key officers and employees;
• our ability to shift a larger percentage of our business mix into IT solutions, project management and business process outsourcing and, if successful, our ability to manage those types of business profitably;
• weakness or reductions in corporate information technology spending levels;
• our ability to maintain existing client relationships and attract new clients in the context of changing economic or competitive conditions;
• the entry of new competitors into the U.S. staffing services and consulting markets due to the limited barriers to entry or the expansion of existing competitors in that market;
• increases in employment-related costs such as healthcare and unemployment taxes;
• the possibility of our incurring liability for the activities of our billable consultants or for events impacting our billable consultants on our clients’ premises;
• the risk that we may be subject to claims for indemnification under our customer contracts;
• the risk that cost cutting or restructuring activities could cause an adverse impact on certain of our operations; and
• adverse changes to management’s periodic estimates of future cash flows that may affect our assessment of our ability to fully recover our goodwill.

Although we believe our estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, management’s assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this report are not guarantees of future performance, and we cannot assure any reader that those statements will be realized or that the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements due to various factors, including the factors listed in this section and the “Risk Factors” section contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this report. We do not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

ZYGO (ZYGO) Board Evaluating Unsolicited Proposal From II-VI

MIDDLEFIELD, CT — (Marketwire) — 01/07/10 — Zygo Corporation (“ZYGO”) (NASDAQ: ZIGO) today announced that its Board of Directors received from II-VI Incorporated (NASDAQ: IIVI) on January 5, 2010 an unsolicited proposal to acquire all of the outstanding shares of common stock of ZYGO for $10.00 per share in cash or II-VI common stock (subject to a limitation on the aggregate amount of II-VI common stock). The Board of Directors will engage an independent financial advisor and evaluate this proposal carefully and pursue the best course of action to enhance value for ZYGO’s shareholders.

Bruce W. Worster, Chairman of the Board of ZYGO, stated, “The Board of Directors will evaluate this proposal in the context of ZYGO’s current strategic plans to increase shareholder value. ZYGO is in the late stages of implementing a substantial reorganization of its business which we believe will strengthen the company’s ability to concentrate on its core markets and technology, and enhance shareholder value. The company is continuing to recognize significant benefits from implementation of its previously announced cost reduction initiatives and completion of sales and other strategic arrangements for its non-core business units. In addition, ZYGO is in the advanced stages of discussions with a dynamic and industry-experienced CEO candidate and with regard to the augmentation of its existing product line in a core competency, which should further increase shareholder value. The Board is optimistic about ZYGO’s future prospects and the shareholder value we expect the company to deliver through its current strategy,” continued Dr. Worster. In addition, J. Bruce Robinson, Chief Executive Officer of ZYGO, said, “Our financial results for fiscal 2010 to date include a number of highlights. Orders have increased quarter on quarter. The increase in customer bookings across virtually all of our markets is an indication that the business environment in these markets appears to be improving, and we anticipate that our margins will continue to improve. Our balance sheet remains strong.”

Zygo Corporation is a worldwide supplier of optical metrology instruments, precision optics, and electro-optical design and manufacturing services, serving customers in the semiconductor capital equipment and industrial markets.

Forward-Looking Statements

All statements other than statements of historical fact included in this news release regarding financial performance, condition and operations, and the business strategy, plans, anticipated sales, orders, market acceptance, growth rates, market opportunities, and objectives of management of the Company for future operations are forward-looking statements. Forward-looking statements are intended to provide management’s current expectations or plans for the future operating and financial performance of the Company based upon information currently available and assumptions currently believed to be valid. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plans,” “strategy,” “project,” and other words of similar meaning in connection with a discussion of future operating or financial performance. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors. Among the important factors that could cause actual events to differ materially from those in the forward-looking statements are fluctuations in capital spending of our customers; fluctuations in net sales to our major customer; manufacturing and supplier risks; risks of order cancellations, push-outs and de-bookings; dependence on timing and market acceptance of new product development; rapid technological and market change; risks in international operations; risks related to the reorganization of our business; dependence on proprietary technology and key personnel; length of the sales cycle; environmental regulations; investment portfolio returns; fluctuations in our stock price; the risk that anticipated growth opportunities may be smaller than anticipated or may not be realized; and the risk related to the Company’s transition to new senior management. Zygo Corporation undertakes no obligation to publicly update or revise forward-looking statements to reflect events or circumstances after the date of this news release. Further information on potential factors that could affect Zygo Corporation’s business is described in our reports on file with the Securities and Exchange Commission, including our Form 10-K, as amended by our Form 10-K/A, for the fiscal year ended June 30, 2009, filed with the Securities and Exchange Commission on September 14, 2009, October 26, 2009, and December 23, 2009 respectively.

Cyclacel’s (CYCC) Seliciclib Found Effective Against Lung Cancer Cell Lines

BERKELEY HEIGHTS, N.J., Jan. 7, 2010 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of two peer-reviewed journal articles featuring the company’s seliciclib (CYC202 or R-roscovitine) drug candidate, an orally available inhibitor of multiple cyclin-dependent kinases (CDKs). CDKs have been extensively investigated as therapeutic targets in light of their frequent deregulation in lung carcinogenesis. In an article published in Clinical Cancer Research, seliciclib was found to be effective in killing lung cancer cells through a novel apoptotic mechanism or induction of cancer cell suicide. Nearly all lung cancer cell lines against which seliciclib was most effective had Ras-activating mutations. Ras is a family of mutations which make lung cancer cells highly resistant to approved drugs such as those targeting epidermal growth factor receptors (EGFR).

“Drugs that target EGFR, such as cetuximab (Erbitux(R)), erlotinib (Tarceva(R)) and gefitinib (Iressa(R)), are active against non-small cell lung cancer (NSCLC). However Ras family mutations, such as K-RAS and N-RAS, in NSCLC patients are associated with increased resistance to treatment. Approximately 15%-30% of patients with NSCLC harbor Ras mutations and have a poor prognosis,” said Professor David Glover, Ph.D., Cyclacel’s Chief Scientist. “The data published in Clinical Cancer Research show a high correlation between Ras mutations and sensitivity to seliciclib. Investigating a correlation between clinical outcomes and Ras mutation status in patients from completed seliciclib trials may provide a rationale to select patients for treatment with seliciclib or other CDK inhibitors based on mutational profile. We look forward to unblinding data from our completed Phase 2, randomized, double-blinded APPRAISE trial in patients with pretreated NSCLC during 2010. If seliciclib is found to be effective in patients with Ras-mutant NSCLC, it could address an area of high unmet medical need.”

Among 52 cell lines of NSCLC origin tested, 2 (4%) were relatively insensitive to seliciclib, 21 (40%) displayed modest sensitivity and 29 (56%) showed marked sensitivity. Of the 13 lung cancer cell lines which had the highest sensitivity to seliciclib, 12 (92%) had Ras-activating mutations, including K-RAS and N-RAS. However of the 15 lung cancer cell lines which were least sensitive to seliciclib, none had Ras-activating mutations.

The Clinical Cancer Research article entitled, “Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe” reported that inhibition of CDK2 by seliciclib suppressed lung cancer growth both in vitro and in vivo of lung cancer cells addicted to CDK2/cyclin E. As a consequence, lung cancer cells underwent apoptosis or cell suicide by induction of a novel mechanism called anaphase catastrophe, as illustrated in the journal’s front cover.

Combining seliciclib with microtubule-targeting agents, such as paclitaxel or docetaxel, was found to be an attractive clinical regimen to consider in patients with lung cancer. The authors also reported studying second-generation CDK inhibitors from Cyclacel with greater potency to seliciclib in terms of inhibiting the growth of lung cancer cells. Citation: Galimberti F., et. al., Clinical Cancer Research, 2010 16:1:109-120.

Seliciclib is currently being evaluated in the APPRAISE trial, a Phase 2b randomized, double-blinded, placebo-controlled trial studying the efficacy and safety of single-agent seliciclib as a third, fourth or fifth line treatment in patients with NSCLC. The trial is using a randomized discontinuation design. The primary endpoint is progression free survival (PFS).

A second peer-reviewed article is entitled “R-roscovitine (seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis”. While CDK inhibitors are known to have clinical activity against B-cell Chronic Lymphocytic Leukemia (B-CLL) cells, this publication directly compares the activity of seliciclib with commonly used therapeutic options, such as the combination of fludarabine and cyclophosphamide. In these ex vivo studies, seliciclib was compared to fludarabine and cladribine given in combination with cyclophosphamide. Seliciclib was found to be the most effective at inducing apoptosis or programmed cell death in malignant B-CLL cells while resulting in significantly less apoptosis induction in “normal” peripheral blood mononuclear cells, suggesting the largest therapeutic window among the treatments studied. Citation: Rogalinska M., et. al., Journal of Cell Biochemistry, 2010 Jan 1, 109:1:217-235.

About seliciclib

Seliciclib is an orally available molecule that selectively inhibits multiple CDK enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been administered to approximately 420 patients in Phase 1 and Phase 2 trials. It is currently being evaluated in the APPRAISE trial, a Phase 2b randomized, placebo-controlled, double-blinded study as a treatment in patients with non-small cell lung cancer (NSCLC) who failed at least two prior therapies and in a randomized Phase 2 study as a single agent in patients with nasopharyngeal cancer.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Risk factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2008, as supplemented by the interim quarterly reports, filed with the SEC.

(c) Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn(R) and Xclair(R) are trademarks of Sinclair Pharma plc. Erbitux(R) is a trademark of Imclone Systems, Iressa(R) is a trademark of AstraZeneca and Tarceva(R) is a trademark of OSI Pharmaceuticals.

India Globalization Capital (IGC) Commissions First Quarry for Commercial Use

BETHESDA, MD–(Marketwire – 01/06/10) – India Globalization Capital, Inc. (AMEX:IGC – News), a company competing in the rapidly growing materials and infrastructure industry in India, today announced that it has commissioned the first of two quarries for commercial production in Maharashtra, India. The second quarry is in the final construction phase and is expected to begin production in the middle of February 2010.

The quarry is located on 10 acres of land leased from the Government of India under a mining license; the second quarry is on 22 acres of land. Combined capacity of the two quarries is projected between 10 million and 11 million metric tons of rock aggregate, representing potential revenue of approximately $40 million, based on current pricing, over five to seven years.

Ram Mukunda, Chief Executive Officer of India Globalization Capital, commented: “We are excited to commission our first quarry, which will strengthen our market position for aggregate sales in Maharashtra, India’s leading industrial state. We see a very strong market for rock aggregate, and we plan to create a pure-play rock aggregate business in India. This industry and investments in this sector are encouraged by the Indian Government, which is offering incentives for the deployment of quarries. With India poised to accelerate its infrastructure build out, the demand for rock aggregate is expected to increase substantially.”

Through its IGC Materials subsidiary, India Globalization Capital produces crushed rock for construction projects in India, where developing infrastructure remains vital to maintaining the country’s economic growth. According to the Freedonia Group, India was the fourth largest aggregate market in the world in 2006, with annual demand of up to 1.1 billion metric tons. Sales have risen an average of 7.7% annually during the past 10 years compared to a global average of approximately 4.4%, with roughly 40% of the demand being for crushed stone. The quarry market is fragmented, with much of India’s aggregate supply coming from small local quarries.

About India Globalization Capital

India Globalization Capital is an infrastructure and materials company operating in India, and builds roads, bridges and highways, and provides materials to the infrastructure industry in India and China. The Company has offices in Maryland, Mauritius, Nagpur, Cochin, Delhi, and Bangalore. For more information about India Globalization Capital, please visit www.indiaglobalcap.com.

Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management’s current views and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, expressed or implied in these statements. Factors that could cause actual results to differ, relate to: (i) ability of the parties to successfully execute on contracts and business plans, (ii) ability to raise capital and the structure of such capital including the exercise of warrants, and (iii) exchange rate changes between the U.S. dollar and the Indian Rupee. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in the company’s definitive proxy statement and supplement filed with the SEC and incorporated by reference into the Form S-3.

Cyclacel Pharmaceuticals (CYCC) to Present at OneMedForum 2010

BERKELEY HEIGHTS, N.J., Jan. 6, 2010 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC – News) (Nasdaq:CYCCP – News) announced today that Spiro Rombotis, President and Chief Executive Officer, will present at the OneMedForum 2010 Finance Conference taking place at the Sir Francis Drake Hotel in San Francisco January 12 -13, 2010. Cyclacel’s presentation will take place on Wednesday, January 13, 2010 at 10:00 a.m. Pacific Time.

Cyclacel’s presentation will be webcast live and archived for 90 days on the Corporate Presentations page of the Cyclacel website at www.cyclacel.com.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Risk factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2008, as supplemented by the interim quarterly reports, filed with the SEC.

The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn(R) and Xclair(R) are trademarks of Sinclair Pharma plc.

Cleveland BioLabs (CBLI) Receives First U.S. Patent for Radiation Protection Drug CBLB502

BUFFALO, NY — (Marketwire) — 01/06/10 — Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that the U.S. Patent and Trademark Office has issued US Patent No. 7,638,485 titled “Modulating Apoptosis” covering the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO), and two additional nations.

Cleveland BioLabs has also filed two additional new patent applications related to Protectan technology in the U.S. around various aspects and properties for CBLB502 and related Protectan compounds, including new methods of use of flagellin derivatives and screening for new compounds with similar properties.

Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted, “With more than 13 sets of patents filed to date in the U.S. and internationally around various properties of CBLB502 and related compounds, we believe we have protected the potentially broad uses of our Protectan technology. The receipt of our first U.S. patent for protection from radiation is a major milestone in our development of CBLB502 and we continue to advance our work in this and other areas of protection from acute stresses.”

About CBLB502

CBLB502 is a derivative of a microbial protein, which has demonstrated the capacity to reduce injury from acute stresses, such as radiation in animal models. CBLB502 mobilizes several cell protective mechanisms, including inhibition of programmed cell death (apoptosis), reduction of oxidative damage and induction of regeneration-promoting cytokines.

CBLB502 is being developed under the U.S. Food and Drug Administration’s Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon/ dirty bomb, or from a nuclear accident. This approval pathway requires demonstration of efficacy in representative animal models and safety and drug metabolism testing in healthy human volunteers.

Evidence of CBLB502’s mechanism of action and activity in animal models was published in Science Magazine in April 2008 (Science, 2008, vol. 320, pp. 226-230). Data from 50 subjects in an initial Phase I safety and tolerability study indicated that CBLB502 was well tolerated and that normalized biomarker results corresponded to previously demonstrated activity in animal models of ARS. There is currently no FDA approved medical countermeasure to treat ARS.

CBLB502 is also being developed as a supportive care measure to reduce and prevent occurrence of side effects of radiotherapy or chemotherapy in cancer treatment.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company’s website at http://www.cbiolabs.com.

TASER (TASR) to Introduce ‘PROTECTOR’ Family Safety Platform

SCOTTSDALE, Ariz., Jan. 6, 2010 (GLOBE NEWSWIRE) — TASER International Inc. (Nasdaq:TASR), a market leader in technologies that protect life, will introduce a groundbreaking new family safety platform called PROTECTOR(TM) during the International Consumer Electronics Show (CES) that runs from January 7-10 in Las Vegas, NV.

PROTECTOR is a revolutionary toolset that gives parents the ability to supervise their children’s mobile phone usage and driving behaviors. Parents can manage the contact lists and content of their child’s mobile phone – including calls, texts, emails, photos and video, and can automatically limit phone functionality to prevent dangerous distractions while driving. PROTECTOR uses integrated GPS, allowing parents to track their child’s location, monitor driving habits, and release vital records to the authorities in emergency situations.

“Our mission at TASER International is to protect life – PROTECTOR is our latest technology breakthrough to further our mission by empowering families to protect the most precious of lives: our children,” says Rick Smith, CEO and founder of TASER International. “Auto accidents are the leading cause of death among American teenagers, and distracted driving is becoming a major factor in these accidents. PROTECTOR will play a significant role in addressing this national tragedy.”

“Keeping my family safe is crucial, but being engaged and staying involved in my kids’ lives is important too. With PROTECTOR, I can do both,” says Smith. “Many kids spend more time with their mobile phone than their families, and most parents have been helpless, in the dark as to who their kids are interacting with and what kind of content their kids are exposed to every day. PROTECTOR empowers parents to stay involved and provide parenting guidance in a fast moving, mobile world.”

PROTECTOR works on multiple devices, each managed through an intuitive control panel accessible through a smart phone, PC, MAC or smart TV. Parents can control who their children interact with and monitor their mobile phone activity and driving behavior at any time – and change permissions and settings in real time. PROTECTOR is carrier-independent and seamlessly connects parents and children, even if they’re on different cellular networks.

Smith adds, “It’s unlike anything on the market today. PROTECTOR is a technologically advanced, yet flexible product suite that grows with the family by providing controls as needs and situations change – from a child’s first mobile phone through the critical teenage years. PROTECTOR adapts as children mature. Through a simple, user-friendly interface, parents can modify parameters or rules anytime.”

TASER will introduce PROTECTOR at CES from booth SOUTH 4 36200 in the Las Vegas Convention Center Thursday, January 7 through Sunday, January 10, 2010. PROTECTOR is anticipated to launch as a subscription service in mid 2010. More information will be available at www.PROTECTOR.com on January 7, 2010.

About TASER International, Inc.

TASER International’s products protect life. TASER provides advanced Electronic Control Devices (ECDs) for use in the law enforcement, medical, military, corrections, professional security, and personal protection markets. TASER devices use proprietary technology to incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens, or themselves in a manner that is generally recognized as a safer alternative to other uses of force. For more information, please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.

The TASER International logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2931

PharmAthene (PIP) Updates Status of BARDA rPA Contract Discussions

ANNAPOLIS, Md., Jan. 5 /PRNewswire-FirstCall/ — PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.  This Special Notice, Solicitation Number: HHSO100200900103C announced BARDA’s intentions to negotiate a contract modification with PharmAthene Inc. for continued development of the Company’s recombinant protective rPA anthrax vaccine candidate, SparVax™.

“We look forward to working closely with BARDA to meet their needs and the critical needs of the Strategic National Stockpile as quickly as possible,” said David P. Wright, PharmAthene’s President and Chief Executive Officer.  “We believe the Special Notice reflects BARDA’s commitment to work with companies to provide funding to advance the development of rPA vaccines and ensure the maintenance of the timeline set under RFP BARDA 08-15 as if a contract had been awarded for our rPA anthrax vaccine candidate under that solicitation.”

This Special Notice appears to be consistent with BARDA’s stated intention to develop and eventually procure a second generation recombinant anthrax vaccine (rPA) for the Strategic National Stockpile, and is consistent with the remarks made by Mr. Wright in an investor teleconference on December 9, 2009 where he described BARDA’s intention to develop and stockpile improved anthrax vaccines as demonstrated by the Special Notice and the ability of PharmAthene to submit a proposal under BARDA Broad Agency Announcement (BAA-09-34).

This Special Notice was published by DHHS as a procedural matter prior to a contract modification.  The Special Notice states, “PharmAthene Inc. has been under contract with the US government since 2003 to develop an rPA vaccine via Contract N01-AI-30052. These development activities were transferred to BARDA as of April 1, 2009 (HHSO100200900103C). This product has matured as demonstrated by successful clinical and non clinical studies. Many of the (R&D) activities that are currently being executed have a direct impact on the government’s urgent need to devise effective measures to protect US citizens from harmful effects of anthrax spores used as instruments of terror.  This contracts increased level of effort does not represent a material difference between the modified contract and the contract that was originally awarded.”  According to the BARDA Special Notice, an amended contract scope of activities include manufacturing activities such as process scale-up and validation, assay validation, and non-clinical safety assessment and study plans.

BARDA announced on December 7, 2009, it has amended an existing Broad Agency Announcement (BAA-09-34) to accommodate proposals for rPA-based vaccine development.  If awarded, the Company’s expectation is that the funding under a BAA contract would be sufficient to advance the rPA vaccine program to the stage of a procurement solicitation.    PharmAthene plans to submit a white paper as required under the BAA instructions by February 1, 2010.

About SparVax™

SparVax™ is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection.  Phase I and Phase II clinical trials involving more than 700 healthy human subjects have been completed and demonstrated that SparVax™ appears to be well tolerated and induces an immune response in humans.  These studies suggest that three doses of SparVax™, administered several weeks apart, should be sufficient to induce protective immunity.  In preclinical studies SparVax™ has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.  PharmAthene’s lead product development programs include (1) SparVax™ – a second generation recombinant protective antigen (rPA) anthrax vaccine, (2) Valortim® – a fully human monoclonal antibody for the prevention and treatment of anthrax infection, (3) Protexia® – a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents, and (4) a third generation rPA anthrax vaccine.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words “appears”; “potential”; “believe”; “anticipate”; “intend”; “intention”; “plan”; “expect”; “estimate”; “could”; “may”; “should”; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company’s development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene’s Forms 10-K and 10-Q under the caption “Risk Factors” and in its other reports filed with the U.S. Securities and Exchange Commission (the “SEC”). In particular, there can be no assurance that the Company will be awarded further government funding to support development of its second generation anthrax vaccine.

Universal Power Group (UPG) Signs Letter of Intent

Jan. 5, 2010 (Business Wire) — Universal Power Group, Inc. (NYSE Amex: UPG), today announced that it has signed a letter of intent to enter into a multi-year battery distribution agreement with K2 Energy Solutions, Inc., a developer and manufacturer of rechargeable battery systems for electric vehicles and energy storage applications.

Under terms of the agreement, UPG will have the rights to market, distribute and sell K2’s complete line of lithium iron phosphate products. These products include batteries, prismatic cells and polymer cells, as well as battery modules, systems and packs. UPG will act as a sales and marketing arm for K2 products, establishing growth opportunities through multiple channels in various markets. K2 will provide manufacturing, engineering and technical expertise, as well as support relating to products covered under the agreement.

“This partnership allows for K2 to leverage UPG’s sales and marketing expertise and established channels of distribution in core market segments for our lithium iron phosphate energy storage solutions,” said Dr. Johnnie Stoker, President and CEO of K2. “We look forward to executing a definitive agreement with UPG that will allow for further mutual growth opportunities.”

“We are pleased to announce this latest step in the development and growth of UPG,” said Ian Edmonds, UPG’s President and CEO. “This agreement matches well with UPG’s long-term strategy of penetrating new markets through strategic alliances, and engaging in new and progressive technologies. Our partnership with K2 provides UPG with exposure to the emerging market for electric vehicles, and serves as another platform for future growth. This agreement highlights the kinds of strategic partnerships we are seeking, and we look forward to working together with K2 over the long term.”

UPG is planning to display a high performance electric vehicle featuring K2 batteries at the International Consumer Electronics Show to be held January 7-10 in Las Vegas. Terms of the distribution agreement are currently being finalized, and both companies anticipate a definitive agreement on or before February 22, 2010.

About Universal Power Group, Inc.

Universal Power Group, Inc. (NYSE Amex: UPG) is a leading supplier and distributor of batteries and power accessories, and a provider of supply chain and other value-added services. UPG’s product offerings include proprietary brands of industrial and consumer batteries of all chemistries, chargers, jump-starters, 12-volt accessories, solar and security products. UPG’s supply chain services include procurement, warehousing, inventory management, distribution, fulfillment and value-added services such as sourcing, battery pack assembly, coordination of battery recycling efforts, and product design and development. For more information, please visit the UPG website at www.upgi.com.

About K2 Energy Solutions, Inc.

K2 Energy Solutions, Inc. is an advanced lithium battery technology company focused on commercialization and manufacture of rechargeable battery systems for electric vehicles and energy storage. The company’s battery systems are based on a lithium iron phosphate cathode material whose inherent safety and low cost makes them ideal for the large format systems required for energy storage and EV applications. K2 differentiates itself as a solutions provider for large format battery packs and systems, developing products based upon customer requirements and utilizing expertise in Lithium Iron Phosphate (LFP) battery chemistry. K2 is a private corporation headquartered in Henderson, Nevada, with manufacturing capabilities in both Nevada and China. Additional information may be found at www.k2battery.com.